Cisplatin/etoposide

Cisplatin/etoposide Reactions 1680, p88 - 2 Dec 2017 Haematological disorders and hair loss: case report An adult woman in her 30’s [exact age at onset not stated] developed grade 4 neutropenia, grade 4 anaemia, grade 3 thrombocytopenia and grade 2 hair loss during treatment with cisplatin and etoposide [dosages, routes, time to reactions onsets and outcomes not stated]. The woman presented with colonic polyposis at the age of 36 and underwent a right hemicolectomy. After the operation, she was given a pathological diagnosis of mixed adenoneuroendocrine carcinoma pT1b N0 M0 stage I. She further developed multiple liver metastases and impaired liver function. She underwent chemotherapy with various drugs but her multiple liver metastases continued to grow larger and she also developed bone, ovary and lymph nodes metastases. Therefore, she was started on third-line chemotherapy with cisplatin plus etoposide. Subsequently, she developed grade 4 neutropenia, grade 4 anaemia, grade 3 thrombocytopenia and grade 2 hair loss. As a result of the ADR’s, she underwent 50% dose reduction of the drugs. The chemotherapy with cisplatin plus etoposide was continued for a further 4 courses but the metastatic lesions developed into progressive disease. As a result, amrubicin monotherapy was administered to the patient as the fourth-line chemotherapy. However, a clinical response was not observed and she died 20 months after the operation due to the metastatic mixed adenoneuroendocrine carcinoma. Author comment: "Therefore, the regimen was changed to cisplatin plus etoposide (EP) as the third-line chemotherapy. In the first course of the chemotherapy, the patient experienced Grade 4 neutropenia, Grade 4 anemia, Grade 3 thrombocytopenia, and Grade 2 hair loss." "[S]ome countries recommend EP regimen for the treatment. . . these regimens have a good response rate, many serious adverse events, particularly hematological toxicity, have been reported." Tagai N, et al. Favorable response of colonic mixed adenoneuroendocrine carcinoma to streptozocin monotherapy. International Cancer Conference Journal 6: 175-179, No. 4, Oct 2017. Available from: URL: http://doi.org/10.1007/ s13691-017-0301-2 - Japan 803285114 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Cisplatin/etoposide

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/cisplatin-etoposide-gyaU0a3uW7
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39019-x
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p88 - 2 Dec 2017 Haematological disorders and hair loss: case report An adult woman in her 30’s [exact age at onset not stated] developed grade 4 neutropenia, grade 4 anaemia, grade 3 thrombocytopenia and grade 2 hair loss during treatment with cisplatin and etoposide [dosages, routes, time to reactions onsets and outcomes not stated]. The woman presented with colonic polyposis at the age of 36 and underwent a right hemicolectomy. After the operation, she was given a pathological diagnosis of mixed adenoneuroendocrine carcinoma pT1b N0 M0 stage I. She further developed multiple liver metastases and impaired liver function. She underwent chemotherapy with various drugs but her multiple liver metastases continued to grow larger and she also developed bone, ovary and lymph nodes metastases. Therefore, she was started on third-line chemotherapy with cisplatin plus etoposide. Subsequently, she developed grade 4 neutropenia, grade 4 anaemia, grade 3 thrombocytopenia and grade 2 hair loss. As a result of the ADR’s, she underwent 50% dose reduction of the drugs. The chemotherapy with cisplatin plus etoposide was continued for a further 4 courses but the metastatic lesions developed into progressive disease. As a result, amrubicin monotherapy was administered to the patient as the fourth-line chemotherapy. However, a clinical response was not observed and she died 20 months after the operation due to the metastatic mixed adenoneuroendocrine carcinoma. Author comment: "Therefore, the regimen was changed to cisplatin plus etoposide (EP) as the third-line chemotherapy. In the first course of the chemotherapy, the patient experienced Grade 4 neutropenia, Grade 4 anemia, Grade 3 thrombocytopenia, and Grade 2 hair loss." "[S]ome countries recommend EP regimen for the treatment. . . these regimens have a good response rate, many serious adverse events, particularly hematological toxicity, have been reported." Tagai N, et al. Favorable response of colonic mixed adenoneuroendocrine carcinoma to streptozocin monotherapy. International Cancer Conference Journal 6: 175-179, No. 4, Oct 2017. Available from: URL: http://doi.org/10.1007/ s13691-017-0301-2 - Japan 803285114 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off